Wagner Wealth Management Corp Acquires New Stake in Becton, Dickinson and Company $BDX

Wagner Wealth Management Corp bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the third quarter, Holdings Channel reports. The fund bought 2,643 shares of the medical instruments supplier’s stock, valued at approximately $473,000.

A number of other hedge funds have also made changes to their positions in the company. BlackRock Inc. purchased a new position in shares of Becton, Dickinson and Company in the second quarter valued at approximately $3,721,533,000. Bank of America Corp DE acquired a new stake in shares of Becton, Dickinson and Company in the second quarter worth approximately $474,993,000. First Eagle Investment Management LLC increased its position in shares of Becton, Dickinson and Company by 15.8% during the second quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock worth $2,090,675,000 after purchasing an additional 1,887,224 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Becton, Dickinson and Company during the second quarter worth approximately $247,372,000. Finally, Deutsche Bank AG purchased a new stake in shares of Becton, Dickinson and Company during the second quarter worth approximately $204,226,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Up 1.6%

Shares of Becton, Dickinson and Company stock opened at $193.77 on Wednesday. The stock has a market cap of $53.39 billion, a P/E ratio of 58.36, a P/E/G ratio of 12.86 and a beta of 0.21. The stock’s 50 day simple moving average is $184.51 and its 200-day simple moving average is $164.26. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $195.99. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The business had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same period in the prior year, the business earned $3.68 earnings per share. The business’s revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th were paid a dividend of $1.05 per share. The ex-dividend date of this dividend was Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s payout ratio is 126.51%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of the company’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the sale, the executive vice president directly owned 19,720 shares in the company, valued at $3,717,022.80. This represents a 0.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the sale, the executive vice president directly owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 6,906 shares of company stock valued at $1,265,855. Insiders own 0.40% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on BDX shares. Barclays assumed coverage on Becton, Dickinson and Company in a research note on Wednesday, October 7th. They issued an “underweight” rating and a $165.00 price objective for the company. Evercore set a $180.00 target price on shares of Becton, Dickinson and Company in a research note on Monday, July 6th. Stifel Nicolaus set a $195.00 target price on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Wolfe Research began coverage on shares of Becton, Dickinson and Company in a research report on Tuesday. They issued an “outperform” rating for the company. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $210.00 target price on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Hold” and a consensus target price of $185.07.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.